ArticleJournal of hematology & oncology2022
A four-stage model for murine natural killer cell development in vivo.
Article in Journal of hematology & oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 19 citations in OpenAlex.
- Myo1g Mediates NKR-P1C Expression in Primary Mouse NK Cells and Participates in Cytotoxicity.Immunology · 2026Article
- Multiparametric Flow Cytometry Panel for Characterization of Mouse T Cell Differentiation and NK Cell Maturation Following Inflammatory Challenge.Methods and protocols · 2026Article
- Targeting SUMOylation Triggers IFN-β-dependent Activation of Patient and Allogenic NK Cells in Preclinical Models of Acute Myeloid Leukemia.Molecular cancer therapeutics · 2026Article
- NK cell allorecognition shapes reprogramming of neutrophils infiltrating heart allografts.bioRxiv : the preprint server for biology · 2025Article
- Translational Insights into NK Immunophenotyping: Comparative Surface Marker Analysis and Circulating Immune Cell Profiling in Cancer Immunotherapy.International journal of molecular sciences · 2025Review
- Suppression of LKB1-mutant lung adenocarcinoma by natural killer cells from females.Journal of the National Cancer Institute · 2025Article
- Ruxolitinib and oHSV combination therapy increases CD4 T cell activity and germinal center B cell populations in murine sarcoma.Molecular therapy. Oncology · 2025Article
- NK Cell Senescence in Cancer: From Molecular Mechanisms to Therapeutic Opportunities.Aging and disease · 2025Review
- NKp46 enhances type 1 innate lymphoid cell proliferation and function and anti-acute myeloid leukemia activity.Nature communications · 2025Article
- NK cell-based immunotherapy strategies for myeloid leukemia.Frontiers in immunology · 2025Review
- Unraveling NK cell heterogeneity through single-cell sequencing: insights from physiological and tumor contexts for clinical applications.Frontiers in immunology · 2025Review
- Treg cells promote decidual vascular remodeling and modulate uterine NK cells in pregnant mice.JCI insight · 2024Article
- Article
- A Flow Cytometry-Based Examination of the Mouse White Blood Cell Differential in the Context of Age and Sex.Cells · 2024Article
- Article
- Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond.Frontiers in immunology · 2023Review
- Natural killer cell homing and trafficking in tissues and tumors: from biology to application.Signal transduction and targeted therapy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Natural killer (NK) cells are the predominant innate lymphoid cells that mediate anti-viral and anti-tumor immunity. NK cells arise from hematopoietic stem cells in the bone marrow (BM) and undergo lineage specification and maturation. Despite the importance of NK cells for innate immunity and the development of innovative cancer therapy, the detailed steps linking NK progenitor (NKP) cell development through immature NK (iNK) cells to mature NK (mNK) cells are poorly defined. In this study, we found that CD49b, NK1.1, and NKp46 are sequentially acquired during the development of murine Lin
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.